Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Mesotherapy and Botulinum Toxin for Non-Scarring Hair Loss: Clinical Uses and Evidence
Description
The presentation reviewed mesotherapy and botulinum toxin for non-scarring hair loss, emphasizing that mesotherapy is a minimally invasive dermal injection technique with its strongest clinical use in alopecia areata and androgenetic alopecia. For alopecia areata, intralesional corticosteroids were highlighted as effective and relatively safe, with betamethasone used successfully in the speaker’s practice. For androgenetic alopecia, the most commonly used mesotherapy agents were minoxidil and 5-alpha-reductase inhibitors such as dutasteride and finasteride; vitamins and growth factors were described as less useful, and growth factors were approached cautiously because of potential tumor risk. The speaker noted that technique, pain control, and adverse effects matter, recommending anesthetic spray and vibration devices, and mentioning possible edema or angioedema and contraindications such as infection, inflammatory scalp disease, and scalp tumors. Evidence suggests men may respond better than women, and the optimal mixture, concentration, and treatment schedule remain uncertain. In contrast, the theoretical rationale for botulinum toxin in androgenetic alopecia was discussed, but the speaker’s randomized, triple-blind, placebo-controlled split-scalp trial found no benefit in hair density, thickness, or miniaturization, and later studies and reviews likewise failed to support its use.
View moreConclusions
- Mesotherapy appears to be a useful minimally invasive option for non-scarring hair loss, especially alopecia areata and androgenetic alopecia, when appropriately selected and delivered.
- Intralesional corticosteroids remain effective for alopecia areata, and low-dose or injectable betamethasone may be a practical, safe alternative to triamcinolone in some settings.
- For androgenetic alopecia, the most supported mesotherapy actives are dutasteride, finasteride, and possibly minoxidil, while routine addition of vitamins or growth factors has weaker justification and may raise safety concerns.
- Growth factors in mesotherapy should be used cautiously because of reported scalp tumor cases and the lack of reassuring safety data.
- Mesotherapy with minoxidil or dutasteride can show good clinical responses in some patients, but benefits may be greater in men than in women and are often modest in monotherapy for female pattern hair loss.
- Pain, edema, and angioedema are relevant adverse effects of mesotherapy, so anesthetic measures and careful screening for contraindications such as infection, inflammatory scalp disease, and tumors are important.
- Vibratory anesthesia and spray anesthetic can meaningfully reduce pain during mesotherapy and improve tolerability in routine practice.
- The theoretical rationale for botulinum toxin in androgenetic alopecia is biologically plausible but remains unproven, despite hypotheses involving improved blood flow and reduced TGF-beta–mediated miniaturization.
- The best available clinical evidence does not support botulinum toxin as an effective treatment for androgenetic alopecia, because randomized data found no meaningful benefit over placebo.
- Overall, botulinum toxin should not be recommended for androgenetic alopecia at present, whereas mesotherapy remains a more promising adjunctive option with still-unsolved questions about ideal drug mixtures, dose, and treatment frequency.
- Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study.#10.1016/j.jaad.2015.04.049
- Betametasona intralesional como opção terapêutica na alopecia areata.
- Dermatol Ther. 2021 Jan;34(1):e14622. doi: 10.1111/dth.14622.#10.1111/dth.14622
- Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.#10.5603/fd.96555
- Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia.#10.5603/fd.96555
- Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients.#10.1111/jdv.18066
- Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia.#10.1111/jocd.12983
- Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
- Mesotherapy with bicalutamide for female pattern hair loss.#10.25259/ijdvl_99_2024
- Frontal edema due to mesotherapy for androgenetic alopecia: A case series.#10.1111/dth.15247
- Angioedema-like contact dermatitis caused by mesotherapy with dutasteride.#10.1111/cod.13585
- Transcutaneous P_o2 of the Scalp in Male Pattern Baldness: A New Piece to the Puzzle.#10.1097/00006534-199605000-00003
- The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism.#10.1016/j.jaad.2020.04.082
- Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia?#10.5603/fd.100354
- Subcutaneous Versus Combined Subcutaneous and Intramuscular Botulinum Toxin for Androgenetic Alopecia: A Randomized Clinical Trial.#10.1016/j.ad.2025.01.012
- Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications.#10.3390/toxins17040163